Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 31, 2007 Brian Orelli	A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note.
The Motley Fool September 12, 2007 Brian Orelli	Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow.
The Motley Fool May 2, 2008 Brian Orelli	Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
BusinessWeek June 11, 2007 Mara Der Hovanesian	Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor, the Marlborough pharmaceutical best known for its sleep drug, Lunesta.
The Motley Fool December 17, 2004 Brian Gorman	Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls.
The Motley Fool October 27, 2006 Brian Lawler	Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool August 25, 2010 Brian Orelli	Shares Soar! That'll Help Investors Sleep Better Tonight. Somaxon finds a marketing partner for its insomnia drug.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool June 11, 2008 Brian Orelli	Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool August 3, 2004 Jeff Hwang	Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool January 31, 2007 Brian Lawler	No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note.
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool March 9, 2004 David Nierengarten	Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%.
The Motley Fool July 28, 2010 Jordan DiPietro	3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage
The Motley Fool July 21, 2006 Brian Lawler	Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool December 3, 2008 Brian Orelli	High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool March 19, 2009 Brian Orelli	Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
The Motley Fool July 16, 2007 Brian Orelli	Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
BusinessWeek January 17, 2005 Weintraub & Barrett	Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool October 31, 2007 Brian Orelli	From Apples to Apple Pie at Teva Year-over-year sales skyrocket at Teva Pharmaceutical, due to the launch of more than 25 new products. Investors, take note.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool January 18, 2008 Brian Lawler	Wrong-Way Regulators in Europe European Union regulators raided operations of multiple large pharmaceutical companies looking for antitrust and anticompetitive actions in both the branded and generic sectors. They're looking in the wrong places.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool September 17, 2009 Brian Orelli	Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it.
The Motley Fool October 26, 2004 Charly Travers	Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land?
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool November 7, 2008 Brian Orelli	Teva's Steady Growth Generic-drug maker Teva Pharmaceuticals has been a good defensive play during the severe downturn in the market.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.
The Motley Fool May 7, 2008 Brian Orelli	Teva's on a Tear The generic-drug maker can't be stopped.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.